Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Ross Procedure May Provide Longer Survival Benefit

By HospiMedica International staff writers
Posted on 04 Sep 2018
A rarely used valve replacement procedure could offer long-term benefits including longer survival, less clotting, and reduced bleeding complications compared to artificial implants, claims a new study.

Researchers at St. More...
Michael’s Hospital (Toronto, Canada), the University of Toronto (UT; Canada), and other institutions conducted a meta-analysis that included randomized clinical trials and observational studies comparing the Ross procedure to a mechanical prosthesis in adults undergoing aortic valve replacement. In all, 18 studies that included 3,516 patients met inclusion criteria, with a median average follow-up of 5.8 years. The pre-specified outcomes were all-cause mortality and long-term outcomes.

The results revealed 46% lower all-cause mortality in those undergoing the Ross procedure, compared with mechanical aortic valves. In addition, patients who underwent the Ross procedure were 58% less likely to die from valve or heart related causes, suffered lower rates of stroke and major bleeding, and experienced a higher quality of life. Conversely, they were also 1.7 times more likely to require a second intervention, likely due to autograft respomse and the fact that two valves are involved, instead of one. The study was presented at the European Society of Cardiology (ESC) annual congress, held during August 2018 in Munich (Germany).

“Ensuring the best outcomes for patients involves tailoring the surgical approach to the patient,” said lead author cardiac surgeon Amine Mazine, MD, of St. Michael's Hospital. “Superior survival with the Ross procedure is likely due to the ability of a living graft to adapt, but this surgery is not for everyone; it needs to be the right patient undergoing the procedure to ensure the best outcomes.”

In the Ross procedure, a diseased aortic valve is replaced with the patient's own pulmonary valve, and pulmonary tissue from deceased donors is then used to replace the switched pulmonary valve. Its use has declined over the past 20 years due to its complexity, increased surgical risk, and potential risk of follow-up procedures. Mechanical valve replacement has also become more common, but patients must take anticoagulants for the rest of their lives to prevent valve clotting and strokes.

Related Links:
St. Michael’s Hospital
University of Toronto

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Syringes
Prefilled Saline Flush Syringes
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.